Page 115 - 2018_12-Haematologica-web

Role of arsenic trioxide in APL
Shpilberg O, Raanani P. The role of mainte- nance therapy in acute promyelocytic leukemia in the first complete remission. Cochrane Database Syst Rev. 2013;(3): CD009594.
8. Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a compari- son of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078–1084.
9. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
10. Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305.
11. Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial. J Clin Oncol. 2017;35(6):605–612.
12. Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelo-
cytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–1283.
13. Kaplan EL, Meier P. Nonparametric estima- tion from incomplete observations. J Am Stat Assoc. 1958;53457–53481.
14. Fine J, Gray R. A proportional hazards model for the subdistribution of a compet- ing risk. J Am Stat Assoc. 1999;94(446)496– 509.
15. Rahmé R, Thomas X, Recher C, et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12): 2422–2424.
16. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population- based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7): 1128–1134.
17. McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133– 136.
18. Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to newly diag- nosed patients with acute promyelocytic
leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9): 1004–1009.
19. Paulson K, Serebrin A, Lambert P, et al. Acute promyelocytic leukaemia is character- ized by stable incidence and improved sur- vival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014;166(5):660–666.
20. Batzios C, Hayes LA, He SZ, et al. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. Am J Hematol. 2009;84(11):715–719.
21. Lobe I, Rigal-Huguet F, Vekhoff A, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia. 2003;17(8): 1600–1604.
22. Andersen MK, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood. 2002;100 (5):1928–1929.
23. Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group expe- rience. J Clin Oncol. 2009;27(16):2668–2676.
haematologica | 2018; 103(12)
2039